Brief: Gyre Therapeutics Announces NMPA Approval For Clinical Trial Evaluating Pirfenidone Capsules In Oncology-Related Pulmonary Complications
31/03/2025 12:14
March 31 (Reuters) - Gyre Therapeutics Inc GYRE.O: GYRE THERAPEUTICS ANNOUNCES NMPA APPROVAL FOR CLINICAL TRIAL EVALUATING PIRFENIDONE CAPSULES IN ONCOLOGY-RELATED PULMONARY COMPLICATIONS Source text: ID:nGNX1FrDcy Further company coverage: GYRE.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Gyre Therapeutics
See all newsBrief: Gyre Therapeutics - Enters Employment Agreement With Ying Luo As CEO - SEC Filing
Gyre Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Gyre Therapeutics, Inc. expected to post a loss of 13 cents a share - Earnings Preview
Brief: Gyre Therapeutics Reports Second Quarter 2026
Gyre Therapeutics Q2 revenue beats estimates on higher ETUARY sales volumes